SI

Shoulder InnovationsA

NYSE / Health Care Equipment & Services

At close

2026-07-18

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

30%

Probability

Target price

$24.00

+11.2% vs current

Most likely

Base case

45%

Probability

Target price

$21.75

+0.7% vs current

B-

Bear case

25%

Probability

Target price

$15.00

-30.5% vs current

AI sentiment snapshot

Latest data as of 2026-07-11

AI commentary

Primary-source evidence is strong for a low-coverage name because the May 13, 2026 earnings 8-K provides specific operating detail, but external confirmation is still thin. News flow in the packet is sparse, analyst-target coverage is limited, and the small-cap medtech setup argues for keeping conviction below average even with a positive directional prior. The tone is best described as cautiously constructive rather than broadly confirmed.

RankAlpha Sentiment Codex - 2026-07-11

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-08-15eventQ1 2026 growth print and raised FY2026 revenue outlook support near-term follow-throughHigh impact

The company reported Q1 2026 net revenue of $16.7 million, up 65% year over year, implant system volume up 51%, gross margin of 77.7%, and raised FY2026 revenue guidance to $65-$68 million; this is the clearest near-term operating proof point in the packet and supports continued monitoring for execution against the higher guide [#SEC-8K-2026-05-13].

2026-09-30catalystJune refinancing reduces a balance-sheet overhang but does not by itself resolve operating cash burnMedium impact

The June 2026 term loan funding was used to repay outstanding debt owed to Trinity Capital, removing a discrete financing overhang, but investors still need evidence that revenue growth can outpace the heavier SG&A and R&D spend seen in Q1 [#8-K-2026-06-29] [#SEC-8K-2026-05-13].

2026-12-31catalystProduct and commercial expansion could sustain adoption if procedure volumes and ASP holdHigh impact

Management tied the Q1 acceleration to more implant systems sold, more customers, a 9% average selling price increase, expanded commercial capacity, and the full commercial launch of the InSet I-135RFX Humeral Stem after added FDA-cleared fracture indications, which together support a multi-quarter adoption case if hospital onboarding continues [#SEC-8K-2026-05-13].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-07-11 • Updated nightlySource: Internal modelMethodology